跳至主要内容
临床试验/NCT06330883
NCT06330883已完成不适用

Determining the Prevalence of Frailty in COVID-19 Patients Admitted to the Intensive Care Unit and Evaluating Its Relationship With Mortality.

Selcuk University1 个研究点 分布在 1 个国家目标入组 148 人开始时间: 2022年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
148
试验地点
1
主要终点
Mortality

研究概览

简要总结

Covid-19 patients admitted to the intensive care unit of Selcuk University Hospital were included in the study. Clinical frailty score was given during admission to the intensive care unit. Demographic data, laboratory data, radiological imaging and vital signs of the patients were recorded. Treatment and patient positions were recorded during the intensive care follow-up of the patients. Mortality status of the patients 6 months after admission to the ICU was recorded.

详细描述

It is planned to include non-pregnant and non-traumatic patients over the age of 18, diagnosed with COVID-19, who are treated in the Intensive Care Unit of Selcuk University Hospital. The frailty status will be evaluated by using the clinical frailty scale at the admission of the patients to the intensive care unit. Evaluation from the patient himself, if the consciousness of the patients is clear; If not, it will be done near the patient. Patients will be divided into two groups using the clinical frailty scale (CFS) as frail if the score is ≥5 and non-fragile if the score is <5. Demographic information and vaccination status (how many dose and type) will be questioned, SOFA score, APACHE II score will be recorded. Routine examinations made from the patient file; thorax computed tomography (CT) imaging, laboratory values, respiratory support information, drug treatments applied, patient positions will be recorded. Thoracic CT scans severity scores for each of the five lung lobes: 0 for no involvement (0%), 1 for minimal involvement (1%-25%), 2 for mild involvement (26-50%), 3 for moderate involvement (51%) -75) and 4 advanced involvement (76-100%). The total severity score will be the sum of the scores of the five lobes. If the score is ≤10, it will be considered as mild involvement, and if the score is >10, it will be considered as severe involvement. Laboratory values; platelet and lymphocyte count, albumin, sodium, ferritin, D-dimer, crp, procalcitonin, interleukin-6 and glomerular filtration rate values, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, CRP/Albumin ratio, arterial blood gas will be recorded. Whether or not he received respiratory support; type (invasive/non-invasive positive pressure respiratory support or high-flow nasal oxygen therapy), duration will be recorded. The use and duration of vasoactive drugs administered, renal replacement therapy and its durations will be recorded. Patient positions will be recorded as supine, lateral decubitus, and prone. The length of stay in the intensive care unit and mortality of the patients will be recorded. Comparisons will be made between frail and non-fragile groups on all these evaluated parameters.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who over the age of 18
  • Patients who diagnosed with Covid-19

排除标准

  • Trauma patient

结局指标

主要结局

Mortality

时间窗: 6 months

Mortality rate in the first 6 months after inyensive care unit admission

次要结局

  • Vasoactive drugs administered(Data will be collected from the admission to the intensive care unit up to 6 months or until mortality within this period.)
  • Patient positions(Data will be collected from the admission to the intensive care unit up to 6 months or until mortality within this period.)
  • The Sequential Organ Failure Assessment Score, The Acute Physiology and Chronic Health Evaluation II Score(First 24 hours after admission intensive care unit)
  • Thorax computed tomography (CT) imaging(Within 2 weeks prior to admission ICU)
  • Respiratory support(As long as the patient stays in the intensive care unit)
  • Laboratory values(Routine values at admission ICU)
  • Length of stay in the intensive care unit(Data will be collected from the admission to the intensive care unit up to 6 months or until mortality within this period.)
  • Renal replacement therapy(Data will be collected from the admission to the intensive care unit up to 6 months or until mortality within this period.)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sinan Degirmencioglu

Research Assistant

Selcuk University

研究点 (1)

Loading locations...

相似试验